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Abstract
Late diagnosis of lung cancer is still the main reason for high mortality rates in lung cancer. Lung cancer is a heterogeneous
disease which induces an immune response to different tumor antigens. Several methods for searching autoantibodies have
been described that are based on known purified antigen panels. The aim of our study is to find evidence that parts of the
antigen-binding-domain of antibodies are shared among lung cancer patients. This was investigated by a novel approach
based on sequencing antigen-binding-fragments (Fab) of immunoglobulins using proteomic techniques without the need
of previously known antigen panels. From serum of 93 participants of the NELSON trial IgG was isolated and subsequently
digested into Fab and Fc. Fab was purified from the digested mixture by SDS-PAGE. The Fab containing gel-bands were
excised, tryptic digested and measured on a nano-LC-Orbitrap-Mass-spectrometry system. Multivariate analysis of the mass
spectrometry data by linear canonical discriminant analysis combined with stepwise logistic regression resulted in a 12-
antibody-peptide model which was able to distinguish lung cancer patients from controls in a high risk population with a
sensitivity of 84% and specificity of 90%. With our Fab-purification combined Orbitrap-mass-spectrometry approach, we
found peptides from the variable-parts of antibodies which are shared among lung cancer patients.
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Introduction
Lung cancer is currently the most common cancer with the
highest mortality rate (28%) in the World due to diagnosis at an
advanced stage.[1,2] However, with the demonstration of a 20%
lung cancer mortality reduction by the NLST trial (National
Cancer Screening Trial) low dose CT screening for lung cancer is
receiving increasing interest.[3] The NELSON trial (Dutch-
Belgian lung cancer screening trial) showed that after three
screening rounds 3.6% of all participants of this study had a false-
positive screen result.[4] Although, still approximately 27% of the
participants were subjected to invasive procedures that revealed
benign lung diseases at baseline screening (first round NELSON
trial).[5] A good biomarker (panel) will reduce this number of
unnecessary invasive procedures. At the moment selection of high
risk individuals for screening is done by age and smoking history.
A biomarker or biomarker panel would be helpful in selecting high
risk individuals for CT screening as this may detect lung cancer at
an earlier stage than CT.
Antibodies can be interesting as markers for distinguishing lung
cancer patients from lung cancer-free individuals. These antibod-
ies are produced by the immune response that target specific
tumor-associated antigens (TAAs) during cancer development,
probably at an early stage.[6–12] Recently Liu et al. showed that
the concentration of circulating IgG autoantibodies against
ABCC3 transporter was significantly higher in female adenocar-
cinoma patients than in female controls [13].
Human antibodies consist of four chains, two identical heavy
chains and two identical light chains. Each light chain has a
variable (VL) and constant (CL) domain. The heavy chains have
three different constant domains (CH1, CH2 and CH3) and a
variable domain (VH). The first constant and variable parts form
the antigen binding fragment (Fab). The remaining two constant
parts of the heavy chain form the Fc region. Within the Fab six
complementarity determining regions (CDR1, CDR2 and CDR3)
are located between frameworks. These CDRs determine the
antigen specificity and form a surface complementary to a shape
that is part of the antigen. CDRs are hypervariable regions of the
antibody.[14] Antibodies, or immunoglobulins, are highly com-
plex molecules with large variation in their amino acid sequence.
The possible diversity in immunoglobulins is estimated between
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1013 and 1050 and therefore the finding of similar or even identical
sequences in different individuals by chance is in theory, highly
unlikely.[14,15] However, studies of different research groups
have recently demonstrated that despite this theoretical small
chance to have identical antibodies among individuals, it is
possible to identify similar or identical sequences.[16–19] A study
performed by us showed that in PNS (paraneoplastic neurological
syndrome) patients identical mutated primary amino acid
sequences of complementarity determining regions (CDRs) exist.
These CDRs are specific for known onconeural antigens, such as
HuD and Yo in PNS patients, and most interestingly were shared
between different PNS patients [20].
The aim of this study is to find evidence that specific antibody
peptides are shared between lung cancer patients in contrast to
lung cancer-free individuals. As lung cancer is a heterogeneous
disease and with the variability of an antibody it might be a
challenge to detect identical tumor-related antibodies in serum.
We experimentally test the hypothesis that specific highly variable
regions of an antibody including complementarity determining
regions (CDRs) can be shared between lung cancer patients. Our
experimental approach to verify this hypothesis is based on
sequencing antibody peptides by mass spectrometry. Measurement
of serum by a mass spectrometer might be too complex due to the
high variability as mentioned above. Purifying IgG Fab from
serum will reduce the complexity of the sample from a lung cancer
patient and will give the possibility to focus on pure antibody
fractions.
Materials and Methods
Ethics and Legal Approval
The NELSON trial was approved by the Dutch Health
Council, the Minister of Health and by the Medical Ethical
Committees of all participating centers (clinical trial number
ISRCTN63545820). All participants for this study provided
written informed consent for the use of their serum samples.
The donor of the reference sample used throughout this study
provided written consent for the use of his/her serum for scientific
purposes according to the guidelines of the Blood Bank Sanquin,
Rotterdam, the Netherlands.
NELSON Trial
The NELSON (Dutch-Belgian Lung Cancer Screening trial)
trial has started recruitment in 2003 by sending questionnaires to
548,489 males and females between 50–75 years of age.
Participants had to be current or former smokers for at least 25
years, smoking at least 15 cigarettes per day or smoking at least 30
years, smoking at least 10 cigarettes per day. From the 548,489
males and females 15,822 participants were included in the trial.
These participants were randomized to a screen or control arm.
The screening arm received CT screening in years 1,2 and 4. The
control arm received no screening (usual care). Participants with a
positive test result were referred to a pulmonologist. If the
diagnosis lung cancer was established the patient was treated and
went off screening. Participants with an indeterminate test result
underwent a follow-up scan three months later. If a negative test
result was obtained the second-round CT scan was scheduled for
12 months later [5,21].
Study Population
For this study, we selected 44 lung cancer cases and 49 controls
(Supplementary Figure S1) from the NELSON lung cancer
screening trial.[5,21] For the cases of the discovery set, NELSON
1, only early stage (I and II) squamous cell (n = 4) or adenocar-
cinomas (n = 21) were selected. They were carefully matched to
the controls by age, gender, smoking status, duration and number
of cigarettes smoked per day, chronic obstructive pulmonary
disease (COPD) status, asbestos exposure and site of blood
sampling (Supplementary Table S1). The selection criteria for
the cases of the NELSON 2 (validation) set (n = 19) were similar,
except that all non-small cell histology’s and disease stages were
allowed (Supplementary Table S1) in order to challenge the results
of the discovery phase. On purpose the clinical characteristics of
the control patients are dissimilar with the NELSON 1 set in
respect to smoking and COPD. Therefore, this NELSON 2 set is
not matched with the NELSON 1 set. By using a validation
sample set (NELSON 2) chosen in this way, the robustness of the
method can be determined.
Serum samples were collected for both NELSON 1 and
NELSON 2 obtained from baseline CT screening (first round).
IgG Fab Purification and NanoLC Orbitrap MS Analyses
Prior to all sample preparation procedures, all samples were
blinded and the key for unblinding was put at the database
coordinator of the NELSON trial. IgG Fab purification and nano-
LC Orbitrap MS analyses were performed according to the
method described before.[22] For a more extended description we
refer to Supplementary Methods S1. In brief, IgG was isolated
from serum and digested into Fab and Fc (Figure 1). The Fab part
was isolated from the digested mixture by SDS-PAGE. The Fab
containing gel bands were excised and tryptic digested. A blank
piece of gel that was not loaded with protein was excised and
treated like the excised Fab bands for background assessment.
LCMS measurements were performed on an Ultimate 3000
nano LC system (Thermo Fisher Scientific/Dionex, Amsterdam,
the Netherlands) online coupled to a hybrid linear ion trap/
Orbitrap MS (LTQ Orbitrap XL; Thermo Fisher Scientific,
Bremen, Germany). 4 mL of the digested Fab was loaded onto the
system. For further settings and solutions we refer to Supplemen-
tary Methods S1 and previous published work.[22] All samples
were randomized before measurement and were measured in
batches of 11 samples including a reference sample. A reference
sample was used as a quality control for each measurement and
analysis step. A blank sample was run at the start and end of the
measurement to determine background and the existence of carry-
over during chromatography.
Data Analyses
Raw data files were loaded into the software Progenesis
(Figure 1) (Version 3.1; Nonlineair Dynamics Ltd, New Castle,
UK) and processes as described previously.[22] In addition, we
performed a Progenesis analysis where instead of detecting
features (peptide masses (m/z)) in all the samples at the same
time by the software program, feature detection was performed
individually per sample. Features picked thereby were matched to
the Progenesis result table containing all samples with a mass
tolerance of 5 ppm. This was of advantage, since often features
occur with low intensities in one sample and are subsequently
matched by Progenesis in all other samples. This result in errors
related to background if one takes the respective mass spectra into
account. With this relative small adjustment it ensures that a
feature is detected more accurately throughout the samples. The
data acquired by this approach was filtered using the same default
settings.[22] A separate data matrix for every case and control was
generated consisting of all features with corresponding raw
abundance and retention time. To generate one large data matrix
that includes all cases and controls from these separate data
matrices, we searched masses from the separate data matrices per
Lung Cancer Patients Are Sharing Antibody Peptides
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case or control in the complete data matrix generated from the
standard Progenesis analyses. Every mass had to meet three
criteria: 1) m/z (65 ppm), 2) retention time (61 min) and 3)
identical charge. If a mass met these three criteria the raw
abundance from the complete matrix (generated by a general
procedure[22] recommended by the manufacturer) was used. If a
mass did not meet these criteria a zero was generated for the raw
abundance.
MS/MS spectra were extracted from raw data files and
converted into Mascot compatible files using extract-msn (part of
Xcalibur version 2.0.7, Thermo Fisher Scientific Inc.). Mascot
(version 2.3.01; Matrix Science Inc., London, UK) was used to
perform database searches against the human subset NCBInr
database (version March 11th, 2009; Homo sapiens species
restriction; 222,066 sequences) of the extracted MS/MS data
(Figure 1). Database (NCBInr) dependent peptide identification
and de novo sequencing results (software PEAKS; Version 5.2;
Bioinformatics Solutions Inc., Waterloo, Canada) were also
included in the Progenesis provided matrix. For settings used for
the database search and de novo sequencing we refer to previous
published work and methods S1.[22] For de novo sequences so far
not known from a database, the Peaks software identifies a leucine
for the isobaric amino acids leucine and isoleucine. Database
dependent peptide identification results or de novo sequencing
results were included in the matrix based on the highest peptide
identity score (Data S1, Data S2 and Data S3). All peptide
sequences from the cases and controls identified by Mascot or
PEAKS were subsequently aligned to databases containing V, D, J
or C-region germline sequences derived from IMGT database
(IMGT, the international ImMunoGeneTics information system
http://www.imgt.org) using the BLAST algorithm (Figure 1).[23]
Peptides with sufficient match (bitscore$12.5 and alignment score
$70%) to the V-region database were assigned to a position on the
immunoglobulin molecule with varying CDR lengths (Data S1,
Data S2 and Data S3).
Raw data files of the reference samples of each data set were
separately loaded into the software Progenesis and followed the
standard procedures as mentioned above. To determine the
proportion of variation between the reference sample measure-
ments performed on different time points, median r-squares were
calculated for each sample. Each sample was compared to all the
other reference samples measured in that dataset and a median r-
square was calculated for each sample. The comparison was based
on the raw abundance of each feature. This was performed
separately for both independent datasets, NELSON 1 and
NELSON 2 (Table S2a and S2b).
To determine the proportion of variation (Figure 1) between the
samples (cases and controls) of the two separate datasets, the same
calculations were performed as described above for each case and
control sample. This analysis was performed separately for the two
datasets (Table S2c and S2d). Based on the distribution of the
median r-squares of each sample, we decided to set a cut-off at r-
square .0.70. The cases and controls that obtained a median r-
square below 0.70 were excluded from the dataset and further
analyses. Calculations were conducted using Microsoft Excel 2007.
Statistical Analysis
Two independent data sets have been used, NELSON 1 and
NELSON 2. The initial step in the statistical analysis consisted of
testing for normality using skewness and kurtosis distribution
characteristics on the intensity of the raw abundance of the
features [24].
Subsequently, univariate analysis was performed, applying
either an unpaired t-test (parametric) or a Mann-Whitney U-test
(non-parametric) to detect significant differences in raw abundance
between cases and controls in the NELSON 1 set.[25] The
significance limit was set at 0.05 (two-sided). All identified features
that were found significantly different were used for the selection of
features to distinguish lung cancer patients from controls.
Secondly, we used for multivariate analysis only the significantly
identified features that had$2 triggered MS spectra. We applied a
Figure 1. Flow-chart of the method and analysis used. In this flow-chart the different steps in Fab purification, Fab measurement and data
analysis are illustrated. In yellow the Fab purification is shown, in blue the mass spectrometry measurement, in green the data analysis and in pink the
statistical analysis.
doi:10.1371/journal.pone.0096029.g001
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multivariate analysis on features fulfilling these criteria with a
(logistic) stepwise regression model (y = a161 + a262 + a363….anxn+
c) in combination with canonical linear discriminant analysis
(Table S3a).[26,27] This resulted in a combination of features with
high sensitivity and specificity in the NELSON 1 dataset. This
combination of features was then tested in the NELSON 2 dataset
using the same methodology as described above.[26,27] Note that
for the NELSON 2 dataset it was necessary to optimize the
coefficients in the model equation in order (Table S3b) to optimize
the sensitivity and specificity in the NELSON 2 dataset.
To avoid a random-error effect in modeling, we verified the
statistical background of the combination of features in a
permutated dataset. The background evaluation consisted of the
same workflow as used for the model building, except that at the
beginning the assignment of cases and controls of NELSON 1
were permutated (Figure S2). This permutation was performed
twelve times and the results obtained were tested for significance
against the model outcome by z-test (one-sided; p,0.05). Since
model building was based on the data as provided in NELSON 1
after which validation of this model was done using the data in
NELSON 2, the same approach was taken after each individual
permutation. Also here, note that for NELSON 2 dataset the
coefficients in the model equation were optimized.
All analyses on model building, validation and background
evaluation were done using STATA, version 12 (StataCorp,
Texas, US). Throughout the study, using two-sided testing (except
for one-sided testing for Z-values), p-values of 0.05 or lower were
considered to be statistically significant. Statistical analyses of the
data shown in Table S1 were generated by SPSS (IBM SPSS
Statistics 20). The time to cancer was generated by calculating the
interval between blood sampling and diagnosis for each case.
Results
Clinical Characteristics of the Study Population
There was no significant difference in the clinical characteristics
between the cases and controls in the NELSON 1 set (Table S1).
In the NELSON 2 set, current or former smoker and COPD
status differed significantly between cases and controls (Table S1).
In 72% and 84% of the cases of the NELSON 1 set, and
NELSON 2 set, respectively, the time interval between blood
sampling and lung cancer diagnosis was between 0–1.5 years. The
median follow-up duration after blood sampling was for the
control population 1925 days (range 1075–2086 days) and 1861
days (range 347–2135) in the NELSON 1 set and NELSON 2 set,
respectively. None of the controls developed lung cancer during
the follow-up period.
Technical Variation
During the mass spectrometry measurements of the biological
samples we measured a reference sample at different time points.
R-square values were calculated from the abundances of identified
proteins in each reference measurement to show technical
reproducibility. The lowest r-square value observed in the different
measurements ranged between 0.84 and 0.93 (Figure 2).
We performed the same r-square calculation for 5 random
biological samples taken from the NELSON 1 set that were
measured on two different LC-columns (same batch) at different
time points. The technical reproducibility within each column
resulted in lowest r-square values ranging from 0.75–0.93, but the
technical reproducibility of the five biological samples measured
on two independent similar columns was lower. For the two
independent similar columns a median r-square of 0.52 was
observed. In Figure 3 the correlation between each sample and
between columns are shown.
In Figure 4A the retention times are shown for peptides
identified with high confidence (Mascot score .60) in the
Reference samples measured concurrently with both NELSON
1 and NELSON 2. This Figure shows that column performance
was comparable between the two different LC columns for these
abundant peptides (r-square 0.996). In addition, the abundances
observed for these peptide also correlated well (Figure 4B; r-square
0.995). This suggests that both chromatography and mass
spectrometry performed nominally, at least for peptides identified
with high confidence at relatively high abundance. Thus, the
technical variation we see primarily stems from peptides at lower
abundances, closer to the detection limits (Figure S3).
An estimation of the biological variation was performed and
resulted in a median r-square of 0.43. This result was much lower
than the lowest r-square (0.84) observed for the technical variation.
Therefore, the biological variation is higher compared to the
technical variation.
These results show that technical variation should be taken into
account and adjustment is needed for comparison of indepen-
dently measured sample sets since the NELSON 1 and NELSON
2 dataset were measured on two different columns at different time
points. To overcome this technical variation, we applied a number
of filters on the data before we could start a data analysis as
described in the Material & Methods section.
With this data we performed separate univariate analysis on all
peptides found in cases and controls from the separate NELSON 1
and NELSON 2 data set. We were able to observe 49 peptides
that were significantly different between cases and controls in the
NELSON 1 dataset. However, these peptides, with one exception,
did not show this difference in the NELSON 2 dataset. There was
no trend observed (r-square 0.004) in p-values for the two datasets.
Therefore, testing univariately in this manner was either not the
right analysis strategy or the process generated randomly selected
features (chance). Therefore, the significant peptides from
NELSON 1 were analyzed as a next step in a multivariate way.
Figure 2. Technical reproducibility of replicate measurements
of the reference sample. Reference sample measured at different
time points during measurement of the NELSON 1 sample set. A
replicate of the reference sample (x-axis) was compared to each other
replicate sample based on the raw abundance of each feature. An r-
square value was calculated. Each dot represents an r-square (y-axis)
value for the comparison of that specific replicate with another
replicate. For each replicate the average r-square and standard
deviation (SD) is shown.
doi:10.1371/journal.pone.0096029.g002
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Figure 3. Technical reproducibility of five biological samples measured on two different columns at different time points. This
dendrogram shows the correlation between five different biological samples measured on two different columns from same batch, column 1 and
column 2 (y-axis). On the y-axis the five different samples are shown. Sample 1–5 are measured on column 1 and 6–10 are measured on column 2.
Sample 1 and 6 are from the same individual. This also applies for sample 2 and 7, 3 and 8, 4 and 9 and 5 and 10. On the x-axis the Euclidian distance
between each sample is shown. A strong correlation per column is found.
doi:10.1371/journal.pone.0096029.g003
Figure 4. LC-MS performance for high abundant peptides in Nelson 1 and Nelson 2. For Reference samples that were measured during
both NELSON 1 and NELSON 2, we compared peptides that were identified with high confidence by a Mascot search with a score of more than 60 in
both sets. For this subset of peptides, we compared the retention times observed in Nelson 1 and Nelson 2 (A) and also their abundance (B). For these
parameters we observed r-square values of 0.996 and 0.995, respectively.
doi:10.1371/journal.pone.0096029.g004
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PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e96029
Antibody Peptide Model
An optimal combination of 12 peptides was identified by the
multivariate statistics used on the NELSON 1 set (discovery set).
This combination of peptides could distinguish lung cancer
patients from controls with sensitivity and specificity of 96% and
100%, respectively. This antibody peptide model was able to
detect lung cancer 373 days on average (range 39–1193 days)
before the diagnosis was determined. In Figure 5 we show that the
combination of the 12 peptides was able to distinguish cases from
controls. The 12 peptides corresponded to 1 sequence overlapping
with the CDR2 region, 1 sequence overlapping CDR3 region, 7
sequences overlapping the Framework 1 region and 3 sequences
overlapping with the Framework 3 region according to the IMGT
database (Table 1).
We performed an external validation in the NELSON 2
(validation) set. When we applied the same 12 peptide model to
this set, cases and controls could no longer be distinguished.
However, with the same peptides but after re-optimization of the
model coefficients, we observed a sensitivity and specificity of 84%
and 90%, respectively. As the coefficients of the equation are
adjusted we had to check for the chance of overfitting of the data.
Therefore, a background evaluation was performed which will be
described later. Within the NELSON 2 validation set the
combination of peptides was able to detect lung cancer 281 days
on average (range 54–777 days) before the diagnosis of lung
cancer.
We compared the raw abundance of the 12 peptides between
the two NELSON datasets. We observed that the average raw
abundance of five peptides was higher in the cases compared to
the average abundance of the controls from the NELSON 1
dataset. These data were consistent with the findings from the
NELSON 2 dataset (Table S4). The other seven peptides had a
higher average raw abundance in the controls of the NELSON 1
dataset compared to the abundance in the cases of this dataset. For
only one of these seven peptides, this difference could be
confirmed in the NELSON 2 dataset (Table S4).
Background Evaluation of Antibody Peptide Model
In addition to the finding of the optimal combination of
peptides which significantly distinguished cases from controls, a
background analysis was performed. As the coefficients of the
equation of the model were adjusted for each dataset we verified
the results for a contribution of random selection of the data and
thereby the chance of finding a comparable model by chance. The
same workflow was applied for the model building except that at
the beginning of the workflow the cases and controls of NELSON
1 were permutated at random (Figure S2). Discovery was
performed in the 12 times permutated NELSON 1 datasets, each
time with 12 different peptides showing the lowest p-value (p,
0.05) in the NELSON 1 set for that particular permutation.
Validation of these models was performed in NELSON 2. The
performance of the multivariate model of the permutated
discovery sets (NELSON 1) is shown in Figure 6A (blue dots)
where the sensitivity is plotted against the specificity. The
corresponding power in the validation sets (NELSON 2) is shown
in Figure 6B (blue dots). Thus, each point in Figure 6A (blue dot)
corresponds with a point (blue dot) in Figure 6B. Also, the
performance found for the actual datasets in which the antibody
peptide model was found is plotted (red dot). It can be observed
that the multivariate fitting from the permutated datasets produces
reasonable models even for permutated data in the discovery set.
However, especially in the validation datasets, the real data
(antibody peptide model) performed significantly better (p,0.05)
than the permutated datasets, suggesting that the immunoglobulin
peptides harbor information related to the disease state of the
patient. Thus, the results we obtained do not stem from an artifact
in the data processing.
CT Screening Result in NELSON 1 and NELSON 2 Dataset
In Figure 7A and 7B the screening results of the baseline CT
scans are shown for the NELSON 1 and NELSON 2 set,
respectively. According to the screening protocol of the NELSON
trial, a repeat CT scan was performed following an indeterminate
screening result, approximately 3 months later.
We observed that 68% of the cases had a positive screening
result in both the NELSON 1 and NELSON 2 set during the first
3 months of the screening program, the other lung cancers were
diagnosed following another repeat CT scan after 3 months or
during the second screening round. After on average 367 days
(range 39–1193 days) for NELSON 1 and 269 days (range 54–777
days) for NELSON 2, the screening result was positive, i.e. suspect
for lung cancer and resulting in clinical work-up by the
pulmonologist and eventually finally diagnosis of lung cancer.
Discussion
By mass spectrometry we found evidence that a proportion of
peptides of the variable part of antibodies differ between lung
cancer patients and controls. A combination of 12 different
peptides was able to distinguish lung cancer patients from controls
in a high risk population. A sensitivity of 96% and a specificity of
100% were observed in the discovery set. An external validation in
an independent case–control set was performed and generated a
sensitivity of 84% and a specificity of 90%. The background
evaluation showed that the 12 antibody peptide model performed
significantly better than a model generated based on permutated
data.
Recently, Arentz et al. published that uniquely mutated V
regions peptides could be used as a proxy for the detection of anti-
Ro52 autoantibodies in sera from primary Sjo¨gren’s syndrome
patients by mass spectrometry.[28] Why these and other studies
were able to identify similar or identical sequences could be
explained by repertoire bias and the convergent evolution of
antibodies during somatic mutation and selection.[19,20] This
selection favors specific alleles and sequences of antibodies with the
optimal affinity towards the specific antigens during immune
response [18,29,30].
We were able to identify peptide sequences which were
distributed differently between lung cancer patients and controls.
The antibody peptide model consisted not only of peptide
sequences positioned at the CDR regions of an immunoglobulin
but also at the framework region surrounding the CDRs. It may
appear surprising that most of the peptides that are represented in
the antibody peptide model derive from framework regions of the
immunoglobulin, rather than from the hypervariable CDRs. This
may be explained by their abundance in the immunoglobulin
pool. Peptides carrying only few mutations relative to the germline
are more likely to occur in several antibody clones, and thus have a
higher abundance. This favors their detection by the mass
spectrometer, especially in samples of high complexity. While
technological advances may enable the reliable quantitation of also
lower abundant peptides, it may even be that hypermutated CDRs
are not as likely to be common among patients sharing an immune
response. But moderately mutated peptides strike the best balance
between specificity, abundance and sharing for the purposes of a
diagnostic marker. The large heterogeneity of lung cancer could
also contribute to the presence of fewer CDR peptides shared
between lung cancer patients.
Lung Cancer Patients Are Sharing Antibody Peptides
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We observed that the average raw abundance of 6 from the 12
peptides was distributed differently in the cases versus controls
between the two datasets. The average raw abundance of these six
peptides was higher in the controls in the NELSON 1 set but in
the NELSON 2 set the average raw abundance was higher in the
cases. This may be due to the increased technical variation we
observed for lower abundance peptides between the sets that were
measured some time apart on different LC columns. While the
system operated nominally for abundant peptides, possibly the
performance close to the detection limit cannot be held constant
over time, affecting reliable detection and quantification of such
peptides.
For our validation set, NELSON 2, we used all disease stages in
contrast to NELSON 1. In NELSON 1 we only used early stage I
and II. Using different stages of lung cancer could also contribute
to the average raw abundance discrepancies between NELSON 1
Figure 5. Distribution of the antibody peptide model outcome of the NELSON 1 and NELSON 2 sets. The raw abundances are filled-in in
the model equation (y = a161 + a262 + a363….anxn+ c) of the relevant sample set. On the y-axis (in arbitrary units) the figures generated by the
equation are shown.
doi:10.1371/journal.pone.0096029.g005
Figure 6. Background determination in NELSON 1 and NELSON 2 datasets. Twelve times a permutation (Background) was performed on
the NELSON 1 and NELSON 2 dataset. The sensitivity and specificity of the antibody peptide model are shown in red. Background assessment: A)
Twelve permutation runs are shown with the corresponding sensitivity and specificity of the NELSON 1 dataset (blue). The same 12 peptides found in
the background evaluation of NELSON 1 were tested in NELSON 2. B) The 12 runs are shown with the corresponding sensitivity and specificity of
NELSON 2 dataset (blue). Note, as some results of the background analysis occurred more than once, a random number between -1 and 1 were
added to each sensitivity and specificity number to make sure each analysis (blue dot) can be seen in the figure.
doi:10.1371/journal.pone.0096029.g006
Lung Cancer Patients Are Sharing Antibody Peptides
PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e96029
and NELSON 2. It could be that tumor-specific antibodies are
more abundant in sera from early stage lung cancer patients
compared to late stage lung cancer patients. We repeated our data
analysis for cohorts that were a mixture of Nelson 1 and -2 data.
While this reduced the clinical differences between the Discovery
and Validation sets, advantages from this improvement were
outweighed by the technical differences between the samples.
While similar trends were observed, they were not as strong as
those shown in Figure 6 (Figure S4).
We also have to cope with the high variability of immunoglob-
ulins, which make the samples probably too complex for the mass
spectrometer. A solution to this problem could be reduction of the
complexity of the sample before it is measured on the mass
spectrometer. This reduction could be established by fractionation
into smaller protein fragments such as Fab-k and Fab-l, or by
producing immunoglobulin fragments containing just the variable
domains of the IgG molecule.
It was our aim to offset biological variation by including a
relatively large number of patients in this study, but unfortunately
large sample numbers translate to extended measurement times of
up to 8 weeks for a dataset. These measurement times introduce
Figure 7. CT scan results of the NELSON 1 and NELSON 2 sample set. CT scan results of the A) NELSON 1 and B) NELSON 2 sample sets are
shown at time of blood sampling (Baseline). Also, CT results are shown of the follow-up CT scan after approximately three months (Follow-up). For
one case from the NELSON 1 set no Follow-up CT scan result was available. The last row represents the numbers of positive, indeterminate and
negative CT scan results of baseline including follow-up results.
doi:10.1371/journal.pone.0096029.g007
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technical variation that counteracts the advantage gained from the
number of included patients.
We were not able to distinguish lung cancer cases from controls
univariately by one peptide. Instead we needed a panel of
different peptides to discriminate significantly between cases and
controls. Lung cancer is a very heterogeneous disease which
results in high variability between patients and cancer types. This
might induce various immune responses to different tumor
antigens.[6–12] Therefore, finding only one antibody that is
shared between all lung cancer patients is highly unlikely.
Brichory et al. for instance showed for PGP 9.5, annexin I and
II a sensitivity of only 14%, 30% and 33%, respectively.[31,32]
Chapman et al. tested a panel of seven TAAs and found a
sensitivity of 41% and a specificity of 93%. Validation of this
panel in an independent sample set showed a sensitivity and
specificity of 47% and 90%, respectively.[33] Koziol et al. were
able to distinguish lung cancer patients from normal individuals
with a panel of seven TAAs. A sensitivity of 80% and a specificity
of 90% were observed, but no validation was performed.[34]
Moreover, Khattar et al. and Zhong et al. were able to identify
validated autoantibody peptide panels for lung cancer screening
with sensitivity and specificity ranging from 84%–91% and 73%–
91%, respectively.[35,36] It is therefore not surprising that no
single peptide could be found in the current data set that
distinguishes cases from controls.
Using a multivariate model, we were able to distinguish lung
cancer patients from controls. However, due to the experimental
and biological variation, it was necessary that we recalibrated our
model for each group of patients. This limits the current
applicability of the method in the clinical practice, at least until
significant technical advances enable a more robust quantifica-
tion and identification of peptides in such complex samples. Still,
we conclude from our data that differences exist between the
immunoglobulin-derived peptides from early lung cancer patients
and controls. This is corroborated by data from earlier studies in
our own group as well as in other research groups that showed
conservation and sharing of rearranged immunoglobulin se-
quences in immunoglobulins against a particular antigen
[19,20,28].
So far, only age and smoking history have been used as selection
criteria for enrolment in screening trials, but it is well known that
even though over 80% of all lung cancer cases are directly related
to smoking, only 11% of female smokers and 17% of male smokers
will be diagnosed with lung cancer during their lifetimes.[37,38]
Therefore, additional diagnostic tests might select high risk
individuals more precise when combined with the selection criteria
age and smoking history in screening trials. The cases and controls
we used for this study were selected based on their diagnosis of
lung cancer within three years (range 39–1193 days) after the
baseline CT scan. Therefore, calculation of sensitivity and
specificity of CT screening in our subset of cases and controls
from the NELSON trial are not applicable in this retrospective
study. However, in this study we have demonstrated that 68% of
the cases were detectable for lung cancer by CT screening. At the
same time point the CT scan was performed, the antibody peptide
model was able to detect lung cancer in 96% and 84% of the cases
in the NELSON 1 and NELSON 2 set, respectively. Eventually
after approximately 1 year the screening result of all cases were
positive by CT screening.
In the high risk population of the NELSON trial still
approximately 27% of the participants are subjected to invasive
and expensive follow-up studies that revealed in benign disease at
baseline CT screening.[5] The performance of CT improves after
follow-up scans, but only after an amount of time has passed, on
average a year for the sets in this study. Thus, there is need for
additional diagnostic capabilities that can improve the perfor-
mance of the current testing at baseline. For example, the group of
Massion recently published their results on a combination of a
serum proteomic biomarker panel with clinical and CT data.[39]
In the current study, we were able to detect lung cancer with an
antibody peptide model in the NELSON 1 and NELSON 2 set
with sensitivities of 96% and 84% and specificities of 100% and
90%, respectively at an early stage. This indicates that specific
antibodies are present at an early disease stage and that such a
panel of antibodies is able to detect lung cancer at an earlier stage
than CT. Auto-antibody profiling has the potential to be a tool for
early detection when incorporated into a comprehensive screening
strategy if technical challenges described in this study can be
overcome.
In conclusion, a panel of antibody peptides is identified that
discriminates samples of lung cancer patients from controls. This is a
first indication that peptides generated from the variable part of
antibodies are shared between lung cancer patients and can be used
to discriminate lung cancer patients and control groups. More
quantitative work is still needed to assess the use of these peptides in
clinical settings.
Supporting Information
Figure S1 Study Flow-chart. A flow-chart diagram of the
samples used in this study. NSCLC: Non-small cell lung
carcinoma.
(TIF)
Figure S2 Statistical analysis flow-chart. Before back-
ground analysis is performed, cases and controls of the NELSON
1 dataset are shuffled randomly.
(TIF)
Figure S3 Variation at different abundances. The abun-
dances of all peptides in the reference sample compared in data
from the Nelson-1 and Nelson-2 datasets. Superimposed, the
subset of peptides that was identified with high confidence, as
plotted in Figure 4B, has been superimposed in red.
(TIF)
Figure S4 The performance of the prediction model was
tested in Training and Testing sets, for both real data,
and data in which the assignment of cases and
controls had been randomized. This approach is the
same as in Figure 6, except that each set was composed of
samples drawn from a combination of both the Nelson-1 and
Nelson-2 sets. We assessed three such combinations, and four
permutations.
(TIF)
Table S1 Clinical characteristics of the NELSON 1 and
NELSON 2 sample sets.
(XLS)
Table S2 A–D. R-square of all reference and clinical
samples of NELSON 1 and NELSON 2.
(XLS)
Table S3 A–B. Regression and canonical discriminant
analyses of NELSON 1 and NELSON 2 datasets.
(XLS)
Table S4 Raw abundance of the 12 antibody peptides in
the NELSON 1 and NELSON 2 dataset.
(XLS)
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Data S1 Data matrix consisting of peptide features
detected by the Progenesis analysis software, the
abundances of these features in the serum samples,
annotation with peptide sequences and alignment
results with an immunoglobulin sequence database.
The data was divided into three segments to improve tractability,
this is segment one.
(ZIP)
Data S2 Data matrix consisting of peptide features
detected by the Progenesis analysis software, the
abundances of these features in the serum samples,
annotation with peptide sequences and alignment
results with an immunoglobulin sequence database.
The data was divided into three segments to improve tractability,
this is segment two.
(ZIP)
Data S3 Data matrix consisting of peptide features
detected by the Progenesis analysis software, the
abundances of these features in the serum samples,
annotation with peptide sequences and alignment
results with an immunoglobulin sequence database.
The data was divided into three segments to improve tractability,
this is segment three.
(ZIP)
Methods S1 Additional detail on sample collection, the study
population, IgG Fab Purification, NanoLC Orbitrap MS analyses
and de novo sequencing.
(DOCX)
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